Get the Stockscreener App
3.73
3.37%
-0.13
Pre-market:
3.75
0.02
+0.54%
Bluebird Bio Inc stock is traded at $3.73, with a volume of 186.35K.
It is down -3.37% in the last 24 hours and down -48.55% over the past month.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
See More
Previous Close:
$3.86
Open:
$3.82
24h Volume:
186.35K
Relative Volume:
0.46
Market Cap:
$36.33M
Revenue:
$21.73M
Net Income/Loss:
$-91.17M
P/E Ratio:
-5.0405
EPS:
-0.74
Net Cash Flow:
$-286.43M
1W Performance:
-9.25%
1M Performance:
-48.55%
6M Performance:
-69.21%
1Y Performance:
-86.58%
1-Day Range:
$3.67
$3.85
1-Week Range:
$3.67
$4.14
52-Week Range:
$3.56
$30.90
Bluebird Bio Inc Stock (BLUE) Company Profile
Name
Bluebird Bio Inc
Sector
Industry
Phone
339-499-9300
Address
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Compare BLUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
3.73 | 36.33M | 21.73M | -91.17M | -286.43M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-15-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-15-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-11-23 | Downgrade | HSBC Securities | Hold → Reduce |
| Dec-08-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-17-23 | Initiated | Cantor Fitzgerald | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-19-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-01-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-28-23 | Initiated | JP Morgan | Overweight |
| Mar-07-23 | Initiated | Robert W. Baird | Outperform |
| Aug-05-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-02-22 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-06-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-07-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Nov-08-21 | Reiterated | Barclays | Equal Weight |
| Nov-08-21 | Reiterated | Canaccord Genuity | Hold |
| Nov-08-21 | Downgrade | Goldman | Neutral → Sell |
| Nov-08-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Nov-08-21 | Reiterated | Wedbush | Neutral |
| Nov-08-21 | Reiterated | Wells Fargo | Equal Weight |
| Aug-10-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-10-21 | Downgrade | Goldman | Buy → Neutral |
| Aug-10-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-10-21 | Resumed | William Blair | Mkt Perform |
| Aug-09-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-01-21 | Downgrade | Berenberg | Buy → Hold |
| Mar-10-21 | Upgrade | Mizuho | Neutral → Buy |
| Feb-17-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-16-21 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-16-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-09-20 | Downgrade | Maxim Group | Buy → Hold |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-05-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-05-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Nov-05-20 | Downgrade | Stifel | Buy → Hold |
| Nov-02-20 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-20-20 | Initiated | Mizuho | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-27-20 | Upgrade | Stifel | Hold → Buy |
| Feb-19-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Feb-03-20 | Resumed | BofA/Merrill | Buy |
| Feb-03-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-13-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-19-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-04-19 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-01-19 | Initiated | Stifel | Hold |
| Aug-12-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-18-19 | Upgrade | Maxim Group | Hold → Buy |
View All
Bluebird Bio Inc Stock (BLUE) Latest News
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc.BLUE - Business Wire
Gene Therapy Market Future Business Opportunities 2025-2032 | - openPR
Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio In $286M Deal - Dealbreaker
Bluebird’s Go-Private Deal Highlights Fraught Life Preserver for Struggling Biotechs - BioSpace
bluebird bio (NASDAQ:BLUE) Coverage Initiated at StockNews.com - Defense World
Stem Cell Therapy Market Growth | Trends, Size & Forecast - openPR
BMS to Acquire Abecma Partner 2seventy bio for $286M - Genetic Engineering & Biotechnology News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc.BLUE - PR Newswire
2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M - BioPharma Dive
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal - Benzinga
Bristol Myers Squibb scoops up 2seventy bio for $286M - The Business Journals
Rhumbline Advisers Cuts Stock Holdings in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
Bluebird bio’s chief medical officer Richard Colvin sells $2,288 in stock - Investing.com Australia
Bluebird bio’s chief commercial officer sells $1,959 in stock - Investing.com
Bluebird bio’s chief commercial officer sells $1,959 in stock By Investing.com - Investing.com Australia
bluebird bio (NASDAQ:BLUE) Coverage Initiated by Analysts at StockNews.com - Defense World
bluebird bio, Inc. Class Action: Levi & Korsinsky Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024BLUE - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio LawsuitBLUE - ACCESS Newswire
Levi & Korsinsky Reminds bluebird bio, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024BLUE - ACCESS Newswire
Lost Money on bluebird bio, Inc. (BLUE)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - ACCESS Newswire
Multiple Myeloma Treatment Market Size Report 2034 | - openPR
Levi & Korsinsky Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024BLUE - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc.(BLUE) Shareholders - ACCESS Newswire
BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
bluebird bio, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your RightsBLUE - ACCESS Newswire
Turbulence at the FDA & bluebird Bio’s sale - STAT
bluebird bio stock slides for second day on buyout news - MSN
Shareholder Rights Advocates at Levi & Korsinsky Investigate bluebird bio, Inc. (BLUE) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Drug and Gene Delivery Devices Market Growth in Future Scope - openPR
Bluebird bio chief business officer Joseph Vittiglio sells $1,759 in stock - MSN
Levi & Korsinsky Reminds bluebird bio Investors of the Ongoing Investigation into Potential Violations of Securities LawsBLUE - ACCESS Newswire
BLUE DEADLINE ALERT: Bernstein Liebhard LLP Reminds bluebird bio, Inc. Investors of Upcoming Deadline - ACCESS Newswire
Shareholders that lost money on bluebird bio, Inc. (BLUE) should contact Levi & Korsinsky about pending Class ActionBLUE - ACCESS Newswire
Contrasting bluebird bio (NASDAQ:BLUE) and Valneva (NASDAQ:VALN) - Defense World
Carlyle and SK Capital’s Acquisition of bluebird bio - Global Legal Chronicle
bluebird bio (NASDAQ:BLUE) Given New $5.00 Price Target at Wells Fargo & Company - Defense World
Bluebird bio stock slides for second day on buyout news (NASDAQ:BLUE) - Seeking Alpha
JPMorgan Upgrades bluebird bio to Neutral From Underweight -February 24, 2025 at 07:36 am EST - Marketscreener.com
JP Morgan Upgrades bluebird bio (BLUE) - Nasdaq
Troubled gene therapy player bluebird sold for a song - pharmaphorum
Amneal pharma, Aramark, Bluebird Bio - TradingView
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital - BioSpace
Bluebird Bio to Be Acquired by Carlyle Group, SK Capital - MSN
StockWatch: Bluebird Bio Plunges on Buyout, as Gene Therapy’s Woes Grow - Genetic Engineering & Biotechnology News
bluebird bio announces take-private deal with Carlyle and SK Capital - MSN
IMMINENT BLUE DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds bluebird bio, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
bluebird bio plunges after take-private deal with Carlyle and SK Capital - MSN
Private equity firms rescue bluebird bio out of its misery - The Pharma Letter
bluebird bio Sees Unusually High Options Volume (NASDAQ:BLUE) - Defense World
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker - MSN
Gene therapy maker bluebird to go private in discounted deal amid cash crunch - MSN
Bluebird Bio Inc Stock (BLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):